Stryker Co. (NYSE:SYK) Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. cut its stake in Stryker Co. (NYSE:SYK) by 2.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 203,311 shares of the medical technology company’s stock after selling 4,683 shares during the quarter. Russell Investments Group Ltd. owned about 0.05% of Stryker worth $73,232,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of SYK. Integrated Wealth Concepts LLC grew its stake in shares of Stryker by 1.0% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 5,629 shares of the medical technology company’s stock valued at $2,034,000 after buying an additional 54 shares during the period. IHT Wealth Management LLC grew its position in Stryker by 55.5% in the third quarter. IHT Wealth Management LLC now owns 2,834 shares of the medical technology company’s stock worth $1,023,000 after acquiring an additional 1,011 shares during the period. Morse Asset Management Inc increased its stake in Stryker by 16.5% during the third quarter. Morse Asset Management Inc now owns 1,410 shares of the medical technology company’s stock worth $509,000 after acquiring an additional 200 shares during the last quarter. Kovitz Investment Group Partners LLC raised its position in Stryker by 60.5% in the third quarter. Kovitz Investment Group Partners LLC now owns 11,691 shares of the medical technology company’s stock valued at $4,223,000 after purchasing an additional 4,406 shares during the period. Finally, EP Wealth Advisors LLC lifted its stake in shares of Stryker by 4.0% in the 3rd quarter. EP Wealth Advisors LLC now owns 196,791 shares of the medical technology company’s stock valued at $71,092,000 after purchasing an additional 7,526 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.50% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Needham & Company LLC restated a “buy” rating and issued a $442.00 price objective on shares of Stryker in a report on Friday, March 21st. Royal Bank of Canada increased their price objective on shares of Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 29th. The Goldman Sachs Group set a $422.00 price target on Stryker in a research note on Tuesday, March 4th. JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a research note on Tuesday, February 18th. Finally, JPMorgan Chase & Co. raised their target price on Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Stryker has an average rating of “Moderate Buy” and an average price target of $421.90.

Stryker Stock Down 6.0 %

Stryker stock opened at $346.14 on Friday. The stock has a 50 day moving average of $381.69 and a two-hundred day moving average of $374.30. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $132.12 billion, a price-to-earnings ratio of 44.61, a PEG ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the business earned $3.46 EPS. As a group, research analysts expect that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.97%. Stryker’s dividend payout ratio is currently 43.30%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.